BOTHELL, Wash., March 14, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a ...

Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million ...

BioLife Solutions, Inc. BLFS, a key player in bioproduction tools and services for cell and gene therapy (CGT) and the broader biopharma market, has unveiled its latest innovation, CryoCase, at the ...

BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter. BioLife Solutions said ...

BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions (BLFS), Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the ...

Northland raised the firm’s price target on BioLife Solutions (BLFS) to $34 from $31 and keeps an Outperform rating on the shares, which were also ...

BOTHELL, Wash., July 15, 2020 /PRNewswire/ --BioLife Solutions, Inc.(NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools ...

We have been happy that BioLife Solutions (BLFS) has gone back to basics and is concentrating (mostly) on what is its most important segment, the biopreservation media (which is 85% of its cell ...

Transaction value based on SEC Form 4 weighted average sale price ($25.72); post-transaction value based on Dec. 4 market close of $25.83 (price not specified in filing). BioLife Solutions is a ...